Aelios Finance has been retained by DBV Technologies to organize its latest capital increase. DBV Technologies is the only company in the world developing a worldwide patented technology plateform able to treat safely food allergy (especially peanut and milk allergy) using a breakthrough method of desensitization by epicutaneous way of administration.
A thorough analysis of the company’s strategy has been conducted with the management and led us to focus the capital raising on specialized funds with a strong pharmaceutical expertise.
DBV Technologies is making its revolutionary treatment a convenient therapy compatible with pharmaceutical standards. It is worth noting that three new investors are specialized funds with strong ties to leading global pharmaceutical companies; Innobio is a fund managed by CDC Entreprises and sponsored by the French state sovereign fund FSI and leading pharmaceutical companies (Sanofi Aventis, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda and Boehringer-Ingelheim); Lundbeckfond Ventures is the Lundbeck Foundation's life science investment entity under Lundbeckfond Invest (owning 70% of the shares of Lundbeck A/S); Shire is a leading global specialty biopharmaceutical company.
“Together with Pierre-Henri Benhamou, co-founder and CEO of DBV Technologies, we have worked as an efficient team and were able to attract top pharma investors who are investing in France for the first time. All this capital raising process has been strongly supported by the existing shareholders especially Rafaèle Tordjman, General Partner, Sofinnova” stated Alain Lostis, General Partner at Aelios Finance
“Aelios’ has made an outstanding contribution to the success of this transaction. We come out of this capital raising exercise with the resources to implement our ambitious strategy and a syndicate of investors that has strong pharmaceutical experience to support it. In addition I must say that I enjoyed working with Alain Lostis whose professional and personal qualities I greatly appreciated” is adding Pierre-Henri Benhamou, DBV’s Founder and CEO
